Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
NCT04680468
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
Researchers are conducting a study to test the safety and effectiveness of a drug called belantamab mafodotin on patients with multiple myeloma. The drug will be given before and after a procedure called autologous stem cell transplantation, along with another drug called lenalidomide. They believe that this treatment will be safe, well-tolerated, and effective in comparison to previous studies.
Researchers are conducting a study to test the safety and effectiveness of a drug called belantamab mafodotin on patients with multiple myeloma. The drug will be given before and after a procedure called autologous stem cell transplantation, along with another drug called lenalidomide. They believe that this treatment will be safe, well-tolerated, and effective in comparison to previous studies.
Third Opinion AI Generated Synopsis
Trial Summary
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and maintenance will be safe, well tolerated, and efficacious in comparison to historical data.
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and maintenance will be safe, well tolerated, and efficacious in comparison to historical data.
from ClinicalTrials.gov
Locations & Contact
Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts:
